[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621238":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":37,"responsibleParty":50,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":69,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Ningbo Medical Center Lihuili Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Initially Unresectable HCC with Conversion Therapy",null,"This cohort consists of patients with hepatocellular carcinoma (HCC) that was initially assessed as unresectable (due to surgical inoperability or oncological unresectability per multidisciplinary team evaluation) but intended for curative treatment. All patients in this cohort received multimodal conversion therapy between January 2018 and December 2024. The therapy aimed to downstage the tumor and primarily included a combination of locoregional therapies (LRT) (such as TACE, HAIC, or radiotherapy) and systemic drug therapy (including anti-VEGF\u002Ftyrosine kinase inhibitors and immune checkpoint inhibitors). Patient data are collected retrospectively from electronic medical records and the HCC clinical database.",[13],"Combination Product: Locoregional Therapy (LRT) + Systemic Drug Therapy",{"label":15,"type":10,"description":16,"interventionNames":10},"Initially Resectable HCC","This cohort consists of patients with hepatocellular carcinoma (HCC) that was initially assessed as resectable and suitable for curative surgery per multidisciplinary team evaluation. All patients in this cohort underwent direct radical resection (curative-intent surgery) as the primary treatment between January 2018 and December 2024, without receiving prior locoregional or systemic conversion therapy. Patient data are collected retrospectively from electronic medical records and the HCC clinical database.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"COMBINATION_PRODUCT","Locoregional Therapy (LRT) + Systemic Drug Therapy","Treatment regimens, doses, and durations varied based on individual clinical decisions and are collected retrospectively.",[9],[24],{"name":25,"affiliation":26,"role":27},"Caide Lu, Professor","Ningbo Medical Centre Lihuili Hospital","PRINCIPAL_INVESTIGATOR",[29,33],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+8613957800900","lucaide@nbu.edu.cn",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Shuqi Mao, Professor","+8617855848257","mmmaoshuqi@163.com",[38],{"facility":26,"status":10,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":10},"Ningbo","Zhejiang","315000","China","CN",{"type":45,"coordinates":46},"Point",[47,48],121.54945,29.87819,{"lat":48,"lon":47},{"type":27,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Caide Lu","Chief Physician","100621238","a-retrospective-study-of-safety-and-efficacy-of-locoregional-therapies-combined-with-anti-vegftkis-and-immune-checkpoint-inhibitors-for-all-comers-of-intention-to-treat-patients-with-unresectable-hepatocellular-carcinoma-100621238",false,"NCT07368023","A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF\u002FTKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Aged 16 years or older.\n* Clinical and\u002For pathological diagnosis of hepatocellular carcinoma (HCC). China Liver Cancer (CNLC) stage I, II, or IIIA.\n* Assessed by a multidisciplinary team (MDT) as having initially unresectable HCC.\n\nExclusion Criteria:\n\n* Presence of extrahepatic metastasis.\n* Presence of Cheng's type IV portal vein tumor thrombus (PVTT).\n* Presence of Cheng's type II or III inferior vena cava tumor thrombus (IVCTT).","ALL","16 Years",{"count":62,"type":63},300,"ESTIMATED","OBSERVATIONAL","This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary objective is to assess the outcomes of intention-to-treat (ITT) patients who received multidisciplinary conversion therapy. This therapy combines locoregional treatments (LRT, such as TACE or radiotherapy) with systemic therapy (anti-VEGF\u002Ftyrosine kinase inhibitors and immune checkpoint inhibitors) with the goal of down-staging tumors to allow for subsequent curative resection.\n\nThe study plans to enroll 300 subjects. The exposure group will include approximately 100 patients with initially unresectable HCC who received the combined conversion therapy between January 2018 and December 2024. A control group of about 200 patients with initially resectable HCC who underwent direct radical surgery during the same period will be used for comparison. Data will be collected retrospectively from hospital electronic medical records and the HCC clinical database, with follow-up until December 2025.",[67,68],"Hepatocellular Carcinoma","Hepatocellular Carcinoma Non-resectable","NOT_YET_RECRUITING","2026-01-20",{"date":72,"type":73},"2026-01-26","ACTUAL",{"date":75,"type":63},"2026-01-25",{"date":77,"type":63},"2026-05-31",{"name":5,"class":6},1]